Logo image of IVA.PA

INVENTIVA SA (IVA.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:IVA - FR0013233012 - Common Stock

3.465 EUR
-0.15 (-4.02%)
Last: 11/21/2025, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to IVA. IVA was compared to 75 industry peers in the Biotechnology industry. IVA has a bad profitability rating. Also its financial health evaluation is rather negative. IVA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IVA had negative earnings in the past year.
In the past year IVA has reported a negative cash flow from operations.
IVA had negative earnings in each of the past 5 years.
In the past 5 years IVA always reported negative operating cash flow.
IVA.PA Yearly Net Income VS EBIT VS OCF VS FCFIVA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -154.84%, IVA is doing worse than 85.33% of the companies in the same industry.
Industry RankSector Rank
ROA -154.84%
ROE N/A
ROIC N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVA.PA Yearly ROA, ROE, ROICIVA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IVA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IVA.PA Yearly Profit, Operating, Gross MarginsIVA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

IVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IVA has been increased compared to 1 year ago.
The number of shares outstanding for IVA has been increased compared to 5 years ago.
Compared to 1 year ago, IVA has an improved debt to assets ratio.
IVA.PA Yearly Shares OutstandingIVA.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IVA.PA Yearly Total Debt VS Total AssetsIVA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

IVA has an Altman-Z score of -5.48. This is a bad value and indicates that IVA is not financially healthy and even has some risk of bankruptcy.
IVA's Altman-Z score of -5.48 is on the low side compared to the rest of the industry. IVA is outperformed by 69.33% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.48
ROIC/WACCN/A
WACC7.78%
IVA.PA Yearly LT Debt VS Equity VS FCFIVA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

A Current Ratio of 0.92 indicates that IVA may have some problems paying its short term obligations.
The Current ratio of IVA (0.92) is worse than 73.33% of its industry peers.
A Quick Ratio of 0.92 indicates that IVA may have some problems paying its short term obligations.
With a Quick ratio value of 0.92, IVA is not doing good in the industry: 70.67% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.92
IVA.PA Yearly Current Assets VS Current LiabilitesIVA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

IVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.14%.
Looking at the last year, IVA shows a very negative growth in Revenue. The Revenue has decreased by -12.84% in the last year.
Measured over the past years, IVA shows a small growth in Revenue. The Revenue has been growing by 5.62% on average per year.
EPS 1Y (TTM)-74.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%

3.2 Future

The Earnings Per Share is expected to grow by 16.26% on average over the next years. This is quite good.
The Revenue is expected to grow by 123.64% on average over the next years. This is a very strong growth
EPS Next Y38.93%
EPS Next 2Y23.83%
EPS Next 3Y13.14%
EPS Next 5Y16.26%
Revenue Next Year-14.87%
Revenue Next 2Y-46%
Revenue Next 3Y70.9%
Revenue Next 5Y123.64%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IVA.PA Yearly Revenue VS EstimatesIVA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
IVA.PA Yearly EPS VS EstimatesIVA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IVA. In the last year negative earnings were reported.
Also next year IVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IVA.PA Price Earnings VS Forward Price EarningsIVA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVA.PA Per share dataIVA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as IVA's earnings are expected to grow with 13.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.83%
EPS Next 3Y13.14%

More info and screens

0

5. Dividend

5.1 Amount

IVA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVENTIVA SA

EPA:IVA (11/21/2025, 7:00:00 PM)

3.465

-0.15 (-4.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2025-11-21
Earnings (Next)02-16 2026-02-16/amc
Inst Owners55.69%
Inst Owner ChangeN/A
Ins Owners6.82%
Ins Owner ChangeN/A
Market Cap505.40M
Revenue(TTM)13.61M
Net Income(TTM)-184.21M
Analysts86.15
Price Target11.64 (235.93%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.12%
PT rev (3m)43.84%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-56.84%
EPS NY rev (3m)-38.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-6.32%
Revenue NY rev (3m)-70.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 54.95
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.62
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0.06
BVpS-0.73
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -154.84%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.12%
ROA(5y)-85.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.41%
Cap/Sales 3.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.92
Quick Ratio 0.92
Altman-Z -5.48
F-Score3
WACC7.78%
ROIC/WACCN/A
Cap/Depr(3y)20.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.77%
Cap/Sales(5y)20.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-71.33%
EPS Next Y38.93%
EPS Next 2Y23.83%
EPS Next 3Y13.14%
EPS Next 5Y16.26%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%10763.41%
Revenue Next Year-14.87%
Revenue Next 2Y-46%
Revenue Next 3Y70.9%
Revenue Next 5Y123.64%
EBIT growth 1Y6.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.67%
EBIT Next 3Y15.84%
EBIT Next 5Y21.53%
FCF growth 1Y-5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.29%
OCF growth 3YN/A
OCF growth 5YN/A

INVENTIVA SA / IVA.PA FAQ

What is the ChartMill fundamental rating of INVENTIVA SA (IVA.PA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to IVA.PA.


What is the valuation status of INVENTIVA SA (IVA.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to INVENTIVA SA (IVA.PA). This can be considered as Overvalued.


Can you provide the profitability details for INVENTIVA SA?

INVENTIVA SA (IVA.PA) has a profitability rating of 0 / 10.


How financially healthy is INVENTIVA SA?

The financial health rating of INVENTIVA SA (IVA.PA) is 0 / 10.